Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reperfusion therapy for stroke.

D Dunbabin1

  • 1University of Tasmania, Hobart.

Australian and New Zealand Journal of Medicine
|June 27, 2000
PubMed
Summary

Aspirin offers modest benefits for acute ischemic stroke within 48 hours. However, anticoagulants like heparin carry bleeding risks, and thrombolytic drugs such as recombinant tissue plasminogen activator (r-TPA) have limited application and require further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiplatelet therapy in the treatment and prevention of vascular disease: some clear answers, some new questions.

Platelets·2010
Same author

Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study.

Stroke·2001
Same author

Effects of spontaneous recanalization on functional and electrophysiological recovery in acute ischemic stroke.

Stroke·1999
Same author

Correlation between functional and electrophysiological recovery in acute ischemic stroke.

Stroke·1999
Same author

Cost-effective intervention in stroke.

PharmacoEconomics·1992
Same author

Aspirin, warfarin, and recurrent stroke.

Lancet (London, England)·1991

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Emergency Medicine

Background:

  • Stroke, primarily ischemic due to arterial occlusion (85% of cases), necessitates effective treatments.
  • Existing treatments for acute ischemic stroke include aspirin, heparin, and thrombolytic agents.
  • The analogy to myocardial infarction treatment suggests clot-dissolving therapies could be beneficial.

Purpose of the Study:

  • To review the efficacy and safety of aspirin, heparin, and thrombolytic drugs in acute ischemic stroke.
  • To evaluate the current data on treatments aimed at dissolving clots in cerebral ischemia.
  • To identify the potential benefits and limitations of various therapeutic interventions.

Main Methods:

  • Review of existing data on aspirin, heparin (unfractionated and low molecular weight), streptokinase, and recombinant tissue plasminogen activator (r-TPA).
  • Analysis of treatment effects on mortality, handicap, and recurrent ischemic events.
  • Examination of safety profiles, particularly hemorrhagic side effects.

Main Results:

  • Aspirin (300 mg daily) shows a modest reduction in mortality and handicap when administered within 48 hours of stroke onset.
  • Heparin administration is associated with significant hemorrhagic side effects, potentially outweighing benefits in reducing recurrent ischemia.
  • Streptokinase increases mortality, while r-TPA may be less hazardous in selected patients, though its use is restricted to a small patient subset based on strict criteria.

Conclusions:

  • Current evidence suggests aspirin provides a modest benefit for acute ischemic stroke.
  • Heparin's risk of hemorrhage limits its utility, and thrombolytic therapy, including r-TPA, requires further research to define optimal patient selection and efficacy.
  • The concept of 'Brain Attack' and urgent stroke assessment needs development to improve patient outcomes.

Related Experiment Videos